The Cytomegalovirus (CMV) Infection market report also offers comprehensive insights into the Cytomegalovirus (CMV) Infection market size, share, Cytomegalovirus (CMV) Infection epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Cytomegalovirus (CMV) Infection market size growth forward.
Some of the key highlights from the Cytomegalovirus (CMV) Infection Market Insights Report:
-
Several key pharmaceutical companies, including Takeda Pharmaceuticals, Roche, Cheplapharm, Helocyte, and others, are developing novel products to improve the Cytomegalovirus (CMV) Infection treatment outlook.
-
In 2023, the United States held the largest market share for cytomegalovirus (CMV) infections, surpassing the EU4 countries (Germany, France, Italy, Spain), the United Kingdom, and Japan. CMV can impact the brain or spinal cord, with the most common clinical manifestations including encephalitis, ventriculoencephalitis, myelitis, polyradiculopathy, and mononeuritis multiplex.
-
Antiviral drugs such as valganciclovir, ganciclovir, cidofovir, foscarnet, or their combinations are prescribed when the infection poses a risk to life or vision. These medications can be administered orally, intravenously, or directly into the eye in severe cases of CMV retinitis. However, these treatments have significant side effects, increasing the demand for more effective therapies.
-
Due to the rarity of CMV, long-term follow-up is essential to understand recurrence and progression-free survival. Transplant recipients are at higher risk for complications and death from CMV. Takeda’s LIVTENCITY specifically addresses the needs of post-transplant patients with CMV.
-
LIVTENCITY was approved by the US FDA in November 2021 as the first drug for treating adults and pediatric post-transplant patients with CMV infection/disease that is resistant to available antiviral treatments. In February 2022, Cheplapharm Arzneimittel GmbH acquired worldwide rights to VALCYTE (valganciclovir hydrochloride) from Hoffmann-La Roche. The European Commission approved LIVTENCITY in November 2022 for post-transplant CMV infections or diseases that do not respond to prior therapies.
-
Pharmaceutical companies continue investing in CMV research and development, driving future market growth. Several therapies are under development for preventing congenital CMV and treating CMV infections in transplant patients, including drugs like Triplex (Helocyte).
-
As per DelveInsight analysis, the Cytomegalovirus (CMV) Infection market is anticipated to witness growth at a considerable CAGR
Strategise your business goals by understanding market dynamics @ Cytomegalovirus (CMV) Infection Market Landscape
Cytomegalovirus (CMV) Infection Overview
Cytomegalovirus (CMV) infections, caused by herpesvirus type 5, can range from mild symptoms like fever and fatigue to severe complications affecting organs such as the eyes and brain. Although common in all age groups, the immune system typically prevents illness in healthy individuals. Blood tests show that 60–90% of adults have had CMV at some point.
In newborns, CMV is often diagnosed by growing the virus from a urine sample, while blood tests can detect a new infection. Ophthalmologists can identify CMV retinitis through eye examinations, and biopsy may be needed for those with weakened immune systems.
CMV infections can lead to serious complications in individuals with compromised immunity, such as transplant recipients. Prevention strategies include preemptive therapy (monitoring for viral replication and providing antiviral treatment) and antiviral prophylaxis (administering drugs to high-risk individuals). Current antiviral treatments for CMV include valganciclovir, ganciclovir, cidofovir, and foscarnet. The infections can result in conditions like retinitis, pneumonia, gastrointestinal ulcers, and encephalitis.
Do you know the treatment paradigms for different countries? Download our Cytomegalovirus (CMV) Infection Market Sample Report
Cytomegalovirus (CMV) Infection Epidemiology Insights
-
In 2023, the United States had the highest number of diagnosed cases of cytomegalovirus infection. The analysis shows that the infection affects both males and females equally. Among the EU4 countries and the UK, France reported the highest number of diagnosed cases, followed by the UK, while Italy had the lowest number of diagnosed cases in 2023.
Cytomegalovirus (CMV) Infection Epidemiology Segmentation
DelveInsight’s Cytomegalovirus (CMV) Infection market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Cytomegalovirus (CMV) Infection historical patient pools and forecasted Cytomegalovirus (CMV) Infection patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Cytomegalovirus (CMV) Infection Market report proffers epidemiological analysis for the study period 2020-32 in the 7MM segmented into:
-
Cytomegalovirus (CMV) Infection Prevalence
-
Age-Specific Cytomegalovirus (CMV) Infection Prevalence
-
Gender-Specific Cytomegalovirus (CMV) Infection Prevalence
-
Diagnosed and Treatable Cases of Cytomegalovirus (CMV) Infection
Visit for more @ Cytomegalovirus (CMV) Infection Epidemiological Insights
Cytomegalovirus (CMV) Infection Market Insights:
-
Major companies like ModernaTX, Helocyte, and others are advancing their leading candidates through various stages of clinical development, focusing on treatments for Cytomegalovirus infections. In 2023, the United States held the largest market share for Cytomegalovirus infections, surpassing the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
Cytomegalovirus (CMV) Infection Market Outlook
The treatment landscape for cytomegalovirus infections, especially in immunocompromised post-transplant patients, is complex and continuously evolving. Prophylactic approaches include preemptive therapy and antiviral prophylaxis, which use sensitive assays for early detection of CMV replication. While vaccines are still under development, treatments like hyperimmune globulin show potential, particularly in preventing vertical transmission in pregnant women. Antiviral drugs such as ganciclovir, valganciclovir, cidofovir, and foscarnet are essential in therapy but come with notable toxicities. Recent treatments like maribavir provide new hope for improved outcomes in both adults and children with post-transplant CMV infection. Despite progress, challenges remain, emphasizing the need for further research and innovation to improve efficacy and reduce side effects in managing CMV infections.
Cytomegalovirus (CMV) Infection Marketed Drugs
-
LIVTENCITY (maribavir): Takeda Pharmaceuticals
-
VALCYTE (valganciclovir hydrochloride): Roche/ Cheplapharm
Cytomegalovirus (CMV) Infection Emerging Drugs
-
mRNA-1647: Moderna
-
TRIPLEX: Helocyte
Cytomegalovirus (CMV) Infection Key Companies
-
Takeda Pharmaceuticals, Roche, Cheplapharm, Helocyte, and others
For more information, visit Cytomegalovirus (CMV) Infection Market Analysis, Patient Pool, and Emerging Therapies
Scope of the Cytomegalovirus (CMV) Infection Market Report:
-
11 Years Forecast
-
7MM Coverage
-
Descriptive overview of Cytomegalovirus (CMV) Infection, causes, signs and symptoms, diagnosis, treatment
-
Comprehensive insight into Cytomegalovirus (CMV) Infection epidemiology in the 7MM
-
Cytomegalovirus (CMV) Infection marketed and emerging therapies
-
Cytomegalovirus (CMV) Infection companies
-
Cytomegalovirus (CMV) Infection market drivers and barriers
Table of Contents:
1 Cytomegalovirus (CMV) Infection Market Key Comprehensive Insights
2 Cytomegalovirus (CMV) Infection Market Report Introduction
3 Competitive Intelligence Analysis for Cytomegalovirus (CMV) Infection
4 Cytomegalovirus (CMV) Infection Market Analysis Overview at a Glance
5 Executive Summary of Cytomegalovirus (CMV) Infection
6 Cytomegalovirus (CMV) Infection Epidemiology and Market Methodology
7 Cytomegalovirus (CMV) Infection Epidemiology and Patient Population
8 Cytomegalovirus (CMV) Infection Patient Journey
9 Cytomegalovirus (CMV) Infection Treatment Algorithm, Cytomegalovirus (CMV) Infection Current Treatment, and Medical Practices
10 Key Endpoints in Cytomegalovirus (CMV) Infection Clinical Trials
11 Cytomegalovirus (CMV) Infection Marketed Therapies
12 Cytomegalovirus (CMV) Infection Emerging Therapies
13 Cytomegalovirus (CMV) Infection: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Cytomegalovirus (CMV) Infection
16 Cytomegalovirus (CMV) Infection Market Key Opinion Leaders Reviews
18 Cytomegalovirus (CMV) Infection Market Drivers
19 Cytomegalovirus (CMV) Infection Market Barriers
20 SWOT Analysis
21 Disclaimer
22 DelveInsight Capabilities
23 About DelveInsight
Related Reports:
Cytomegalovirus (CMV) Infection Epidemiology 2034
DelveInsight’s “Cytomegalovirus (CMV) Infection – Epidemiology Forecast to 2034” report delivers an in-depth understanding of the disease, historical and forecasted Cytomegalovirus (CMV) Infection epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Cytomegalovirus (CMV) Infection Pipeline 2024
“Cytomegalovirus (CMV) Infection Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Cytomegalovirus (CMV) Infection market. A detailed picture of the Cytomegalovirus (CMV) Infection pipeline landscape is provided, which includes the disease overview and Cytomegalovirus (CMV) Infection treatment guidelines.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/